Text Size

An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy

This study has been terminated.
(Low Recruitment)
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00721981
First received: July 23, 2008
Last updated: December 9, 2010
Last verified: December 2010
History of Changes

July 23, 2008
December 9, 2010
April 2009
Not Provided
To obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC stage IIb/IV who are in transition from 1st line to 2nd line treatment [ Time Frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00721981 on ClinicalTrials.gov Archive Site
  • current medical practice treatment objectives and modalities side effects [ Time Frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy ] [ Designated as safety issue: No ]
  • socioeconomic status and demographics patients' perception of their health status and treatment patient values and patient preferences [ Time Frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy
A Non-interventional Study for Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy. With Special Focus on Patients Who Are in Transition From First Line to Second Line Treatment

The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients suffering from non-small cell lung cancer (NSCLC) (stage IIIb and IV) undergoing chemotherapy, who are in transition from 1st to 2nd line treatment.
  • Lung Cancer
  • Non-small Cell Lung Cancer
Not Provided
1
Regular treatment for non-small cell lung cancer (NSCLC)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
120
October 2009
Not Provided

Inclusion Criteria:

  • Patients suffering from non-small cell lung cancer (NSCLC) with clinical stage IIIB and IV tumours
  • Patients with one chemotherapy regimen (first line treatment) (adjuvant chemotherapy following surgery is also regarded as first line treatment)
  • Patients who are in transition from first to second line treatment
  • Patients who signed an informed consent

Exclusion Criteria:

  • Chemotherapy naïve patients
  • Patients ever enrolled in clinical studies treating non-small cell lung cancer (NSCLC) with chemotherapy (during 1st and 2nd line chemotherapy)
  • Patients who ever had chemotherapy for an indication other than NSCLC
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00721981
NIS-ODE-DUM-2008/1
No
Chris Teale, Director Global Pricing & Market Access (Oncology), AstraZeneca UK Limited
AstraZeneca
Not Provided
Study Director: Christopher Teale AstraZeneca UK Limited, Alderley House, Alderley Park, Macclesfield SK10 4TF, Cheshire, United Kingdom, Phone: +44 1625 516549 Fax: +44 1625 518982
Study Chair: Oliver Fietz, PhD AstraZeneca GmbH, Tinsdaler Weg 18322880, Wedel, Germany, Phone: +49 (0) 4103 708-3096 Fax: +49 (0) 4103 708-7-3096
Principal Investigator: Helge Bischoff, MD Thoraxklinik Heidelberg, gGmbH, Amalienstr. 5, 69126 Heidelberg, Germany, Phone: +49 (0) 6221 396-1304 Fax: +49 (0) 6221 396-1305
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP